Get the Stockscreener App
2.00
4.31%
-0.09
After Hours:
2.05
0.05
+2.50%
Cytomx Therapeutics Inc stock is traded at $2.00, with a volume of 1.70M.
It is down -4.31% in the last 24 hours and up +7.53% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$2.09
Open:
$2.08
24h Volume:
1.70M
Relative Volume:
0.66
Market Cap:
$329.83M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-100.00
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
-12.28%
1M Performance:
+7.53%
6M Performance:
+234.00%
1Y Performance:
+60.00%
1-Day Range:
$2.00
$2.115
1-Week Range:
$2.00
$2.30
52-Week Range:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.00 | 341.37M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX at Morgan Stanley Conference: Innovative Oncology Advances - Investing.com
Transcript : CytomX Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 01 - MarketScreener
Is CytomX Therapeutics Inc. stock showing strong momentumVolume Spike & Technical Buy Zone Confirmations - Lancaster City Council
Can CytomX Therapeutics Inc. navigate macro headwindsJuly 2025 Macro Moves & Verified Trade Idea Suggestions - Lancaster City Council
Published on: 2025-09-09 06:04:45 - beatles.ru
RA Capital Management L.P. Invests $636,000 in CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics Inc.’s volatility index tracking explained2025 Top Decliners & Safe Capital Growth Tips - Newser
How to recover losses in CytomX Therapeutics Inc. stockWeekly Trend Summary & Verified Momentum Stock Ideas - Newser
Is CytomX Therapeutics Inc. stock bottoming out2025 Pullback Review & Reliable Breakout Forecasts - Newser
CytomX Therapeutics Inc. Building a Base Near Support2025 Buyback Activity & Entry Point Strategy Guides - beatles.ru
Is CytomX Therapeutics Inc. forming higher highs and higher lowsBear Alert & Short-Term Swing Trade Alerts - خودرو بانک
Will CytomX Therapeutics Inc. benefit from AI trendsPortfolio Risk Summary & Free Expert Approved Momentum Trade Ideas - خودرو بانک
Can CytomX Therapeutics Inc. maintain sales growthJuly 2025 Market Mood & Technical Buy Zone Confirmation - خودرو بانک
Identifying reversal signals in CytomX Therapeutics Inc.2025 Historical Comparison & Risk Controlled Daily Plans - Newser
News impact scoring models applied to CytomX Therapeutics Inc.July 2025 Spike Watch & Expert Approved Momentum Trade Ideas - Newser
How to forecast CytomX Therapeutics Inc. trends using time seriesJuly 2025 Gainers & Community Supported Trade Ideas - Newser
Should you hold or exit CytomX Therapeutics Inc. nowTrade Risk Assessment & Reliable Price Action Trade Plans - Newser
Historical volatility pattern of CytomX Therapeutics Inc. visualizedMarket Growth Summary & Free High Accuracy Swing Entry Alerts - Newser
Statistical indicators supporting CytomX Therapeutics Inc.’s strengthWeekly Loss Report & Consistent Return Strategy Ideas - Newser
Can you recover from losses in CytomX Therapeutics Inc.Market Movement Recap & Fast Entry Momentum Alerts - Newser
Is CytomX Therapeutics Inc. vulnerable to short sellersQuarterly Investment Review & Safe Capital Allocation Plans - خودرو بانک
Sentiment analysis tools applied to CytomX Therapeutics Inc.Quarterly Portfolio Report & Consistent Return Strategy Ideas - Newser
CytomX Therapeutics Inc. stock trend forecast2025 Macro Impact & AI Forecasted Stock Moves - Newser
Will CytomX Therapeutics Inc. stock recover after recent dropInsider Selling & Weekly Chart Analysis and Guides - Newser
Real time social sentiment graph for CytomX Therapeutics Inc.July 2025 Movers & High Accuracy Swing Entry Alerts - Newser
Technical analysis overview for CytomX Therapeutics Inc. stock2025 Bull vs Bear & Momentum Based Trading Signals - Newser
What institutional flow reveals about CytomX Therapeutics Inc.Market Performance Recap & Real-Time Sentiment Analysis - Newser
Is CytomX Therapeutics Inc. showing signs of accumulationJuly 2025 PreEarnings & Accurate Intraday Trade Tips - Newser
Will CytomX Therapeutics Inc. benefit from macro trends2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
CytomX Therapeutics Inc. stock trendline breakdownJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - Newser
Leading vs lagging indicators on CytomX Therapeutics Inc. performanceMarket Growth Review & Accurate Technical Buy Alerts - Newser
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
Published on: 2025-09-03 09:30:47 - Newser
What earnings revisions data tells us about CytomX Therapeutics Inc.Weekly Stock Recap & Long-Term Growth Plans - Newser
Published on: 2025-09-03 13:30:24 - beatles.ru
What earnings revisions data tells us about CytomX Therapeutics IncJuly 2025 Levels & Weekly Momentum Stock Picks - Newser
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below Fifty Day Moving AverageHere's Why - MarketBeat
Will Windtree Therapeutics Inc. outperform during market ralliesJuly 2025 Short Interest & Fast Moving Trade Plans - خودرو بانک
Market Outlook: Will CytomX Therapeutics Inc. benefit from AI trendsJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - خودرو بانک
Is CytomX Therapeutics Inc. trading at a discountJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - خودرو بانک
Will CytomX Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):